164 related articles for article (PubMed ID: 28334539)
1. [Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm].
Haluzík M
Vnitr Lek; 2017; 63(2):87-92. PubMed ID: 28334539
[TBL] [Abstract][Full Text] [Related]
2. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
[TBL] [Abstract][Full Text] [Related]
3. Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes.
Khunti K; Cos X; Rutten G
Prim Care Diabetes; 2014 Jul; 8(2):119-25. PubMed ID: 24207030
[TBL] [Abstract][Full Text] [Related]
4. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.
Shaefer CF; Anderson J
Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422
[TBL] [Abstract][Full Text] [Related]
5. A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus.
Kalra S; Gupta Y
J Pak Med Assoc; 2016 Mar; 66(3):360-1. PubMed ID: 26968297
[TBL] [Abstract][Full Text] [Related]
6. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
Lajara R; Cengiz E; Tanenberg RJ
Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
[TBL] [Abstract][Full Text] [Related]
7. Novel and Emerging Insulin Preparations for Type 2 Diabetes.
Cheung KK; Alexander P
Can J Diabetes; 2015 Dec; 39 Suppl 5():S160-6. PubMed ID: 26653255
[No Abstract] [Full Text] [Related]
8. Insulin degludec. Uncertainty over cardiovascular harms.
Prescrire Int; 2014 Jun; 23(150):149. PubMed ID: 25121146
[TBL] [Abstract][Full Text] [Related]
9. Basal insulin therapy in type 2 diabetes.
Bethel MA; Feinglos MN
J Am Board Fam Pract; 2005; 18(3):199-204. PubMed ID: 15879567
[TBL] [Abstract][Full Text] [Related]
10. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
Goldman J; Kapitza C; Pettus J; Heise T
Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
[TBL] [Abstract][Full Text] [Related]
11. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
Nadeau DA
Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
[TBL] [Abstract][Full Text] [Related]
12. The past, present, and future of basal insulins.
Pettus J; Santos Cavaiola T; Tamborlane WV; Edelman S
Diabetes Metab Res Rev; 2016 Sep; 32(6):478-96. PubMed ID: 26509843
[TBL] [Abstract][Full Text] [Related]
13. [Insulin therapy-new insulin analogues].
Ehren M; Klein HH
Internist (Berl); 2019 Sep; 60(9):887-894. PubMed ID: 31396651
[TBL] [Abstract][Full Text] [Related]
14. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
15. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
Vedtofte L; Knop FK; Vilsbøll T
Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
[TBL] [Abstract][Full Text] [Related]
16. Current usage of long-acting insulin analogs in patients with type 2 diabetes mellitus.
Aktas G; Taslamacioglu Duman T
Expert Rev Endocrinol Metab; 2024 Mar; 19(2):155-161. PubMed ID: 38375790
[TBL] [Abstract][Full Text] [Related]
17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
18. Switching basal insulins in type 2 diabetes: practical recommendations for health care providers.
Anderson SL; Trujillo JM; Anderson JE; Tanenberg RJ
Postgrad Med; 2018 Mar; 130(2):229-238. PubMed ID: 29260929
[TBL] [Abstract][Full Text] [Related]
19. Effect of Newer Long-Acting Insulins on Hypoglycemia and Fracture Risk Among People with Diabetes: A Systematic Review.
Hangaard S; Jensen MH
Curr Osteoporos Rep; 2021 Dec; 19(6):637-643. PubMed ID: 34741730
[TBL] [Abstract][Full Text] [Related]
20. New developments in diabetes management: medications of the 21st century.
Fonseca VA
Clin Ther; 2014 Apr; 36(4):477-84. PubMed ID: 24594068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
